TNFRSF4 and melanoma: Esteban et al. demonstrated that an OX40 agonist combined with a peptide vaccine inhibits tumor growth by enhancing the immune response of CD4+ T cells and prolongs survival in a mouse model of melanoma (Kumai et al. 2017).